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Increasing the penetration of drugs within solid tumors can be accomplished through mul-
tiple ultrasound-mediated mechanisms. The application of ultrasound can directly change
the structure or physiology of tissues or can induce changes in a drug or vehicle in order to
enhance delivery and efficacy. With each ultrasonic pulse, a fraction of the energy in the
propagating wave is absorbed by tissue and results in local heating. When ultrasound is
applied to achieve mild hyperthermia, the thermal effects are associated with an increase in
perfusion or the release of a drug from a temperature-sensitive vehicle. Higher ultrasound
intensities locally ablate tissue and result in increased drug accumulation surrounding the
ablated region of interest. Further, the mechanical displacement induced by the ultrasound
pulse can result in the nucleation, growth and collapse of gas bubbles. As a result of such
cavitation, the permeability of a vessel wall or cell membrane can be increased. Finally,
the radiation pressure of the propagating pulse can translate particles or tissues. In this
perspective, we will review recent progress in ultrasound-mediated tumor delivery and the
opportunities for clinical translation.
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THE PROBLEM
The goal of this Frontiers issue is to explore methods to enhance
the penetration of drugs within solid tumors. Combining ultra-
sound with a drug does indeed have the potential to enhance
delivery; however, due to the requirement to guide the beam to
the tumor such treatment will be a possibility only for localized
primary tumors and well-characterized metastases that are acces-
sible to sound waves. Ultrasound is easily directed to superficial
organs such as the breast and prostate, as well as most abdomi-
nal organs, and has also been applied in the treatment of brain
tumors. The effects of high intensity ultrasound on biological tis-
sue, and particularly on the central nervous system, have been
recognized for more than 70 years; the ability to heat and ablate
tissue was described initially (1–5). Within studies in the 1940s and
1950s, ultrasound was also determined to have non-thermal effects
on tissue, typically characterized as mechanical effects (6). The
mechanical effects of ultrasound can act directly upon the tumor
tissue or on injected microbubbles whose oscillations enhance
vascular or cell membrane permeability. Although early studies
were not geared toward drug delivery, these same mechanisms
of high temperature ablation or mild hyperthermia can increase
drug accumulation within a lesion and lesion boundary. In recent
strategies, the increased temperature is applied to influence both
the tissue and the drug capsule.
ENHANCED EXTRAVASATION OF NANOTHERAPEUTICS
THROUGHMECHANICAL AND THERMAL EFFECTS ON TISSUE
The direct effects of ultrasound on tissue and vasculature have
been reported to enhance the extravasation of antibodies and
nanotherapeutics (7–9). In some cases, the mechanical effects of
ultrasound have been shown to enhance therapeutic penetration.
With a center frequency of 1 MHz ultrasound at a peak nega-
tive pressure (PNP) of 8.95 MPa, antibody penetration has been
shown to be enhanced at the tumor periphery,presumably through
mechanical effects (8). The compression and rarefaction resulting
from the ultrasound wave can produce the nucleation, growth, and
collapse of gas bubbles within tissues. Such cavitation is assumed
to facilitate transport within tumor tissue.
The thermal dose delivered by ultrasound is typically mea-
sured in cumulative equivalent minutes at 43°C (CEM 43) which
is defined as tR(43−T ), with t being the time of treatment, T
the average temperature during treatment, and R a constant that
equals 0.25 for temperatures between 37 and 43°C and 0.5 above
43°C (10, 11). Hyperthermia has been demonstrated to increase
tumor blood flow and microvascular permeability (12). While it
has long been recognized that heat increases the accumulation
of small particles in the heated region of interest, the typical
protocol has involved 1 h or more of heating. However, by combin-
ing the mechanical and thermal effects of ultrasound, enhanced
delivery has been achieved with a shorter treatment (13). In
such studies, the temperature goal is ∼41–42°C and insonation
continued for ∼5–20 min. As a result of hyperthermia and the
mechanical effects of ultrasound, we have observed that the accu-
mulation of liposomes in an insonified tumor can be increased
up to threefold to as much as 22%ID/g. While ultrasound was
shown to enhance accumulation in syngeneic murine tumors, the
ultrasound parameters that were required to enhance nanopar-
ticle accumulation were shown to differ between epithelial and
epithelial-mesenchymal transition (EMT) tumor phenotypes (7).
While mild hyperthermia enhanced accumulation in the epithe-
lial tumors, likely through decreased intratumoral pressure and
enhanced apparent permeability, higher ultrasound pressure was
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required to enhance delivery in the poorly vascularized EMT phe-
notype. Further, excessive temperature or thermal dose can result
in vascular stasis, particularly in highly vascular epithelial tumors.
The requirement to personalize the ultrasound parameters to the
tumor biology will likely require image guidance to insure clinical
success.
In part due to the differing effects of mild hyperthermia with
tumor biology, the use of high temperature ablation to enhance
delivery has been explored as a methodology that is likely to be
generally effective in increasing delivery. While it seems coun-
terintuitive that tissue ablation can greatly enhance accumulation,
edema, enhanced blood flow, and increased transport in the region
surrounding the ablated site can successfully improve delivery. In
our experience, the peak delivery in regions surrounding ablation
can exceed 30%ID/g. Also of clinical interest, the hyperthermia
surrounding radiofrequency (rf) ablation lesions has been used to
enhance local delivery; however, the temperature obtained with
such devices ranges from 50 to 90°C (14). Rf ablation has been
applied in previous studies to achieve a similar enhanced delivery,
and such techniques are now in clinical trials (15, 16). High inten-
sity focused ultrasound similarly enhances delivery surrounding
the site of ablation, although combinations of ablation and drug
delivery remain primarily under pre-clinical investigation.
RELEASE OF DRUG FROM NANOPARTICLES WITHIN THE
VASCULATURE
Nanoparticles that can be triggered to release a small molecule
cargo within a tumor have shown the potential to increase both
the local concentration of the drug and tumor penetration. Yet, the
challenge of developing particles that are stable in circulation and
release their cargo upon activation has long been recognized as
a major challenge in pharmaceutical development. While many
activatable particles are under development (11, 17–23), ther-
mally sensitive liposomes have been frequently combined with
ultrasound in recent pre-clinical and clinical studies and will be
considered here. In studies of thermally sensitive liposomes, imag-
ing has been used to verify that amphipathic cargo released within
the tumor vasculature remains concentrated within the tumor in
the region of release (18). We have found that release of drug
from such temperature-sensitive vehicles can be highly effective,
resulting in a complete response in aggressive murine tumors
(unpublished data).
Temperature-sensitive liposomes were initially proposed con-
taining 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)
with a phase transition of Tm=∼41°C and multiple formulations
containing DPPC have been proposed (24, 25). The incorpora-
tion of lyso-phospholipids in DPPC-based liposomes decreases
the phase transition temperature and speeds the release of the
cargo, likely due to the creation of local defects within the lipid
bilayer (26). The Thermodox™ formulation, with the incorpora-
tion of a lyso-phospholipid, releases at a clinically desirable tem-
perature of ∼39°C. The incorporation of the lyso-phospholipids
also enhances the ion permeability and drug release rates at the
membrane phase transition (27). Unfortunately, using the con-
ventional ammonium sulfate loading, liposomes containing lyso-
phospholipids also rapidly release their cargo within the blood
pool. As a result, while local delivery can be achieved within tens
of minutes after injection, the dose limiting toxicities of such for-
mulations have typically limited their application to single dose
administration. Although the pre-clinical data using Thermodox
has been very exciting, this activatable doxorubicin formulation
reportedly failed to meet its primary endpoint in the Phase III
HEAT Study in patients with hepatocellular carcinoma (HCC).
Yet, in spite of this setback, the potential for temperature-sensitive
vehicles to have a significant impact on the concentration and
penetration of drugs within solid tumors is substantial. Although
early clinical studies have typically been limited to one-time
treatment, with new formulations repeated treatment should be
feasible and the resulting clinical impact enhanced. Multiple alter-
native formulations have been proposed and compared and have
been shown to enhance circulation time (25, 28–30). Alterna-
tive strategies using metal-drug complexes, a Brij surfactant and
phosphatidylglycerol have been reported to enhance the stability
of temperature-sensitive liposomes and are promising alterna-
tives for future investigation. The ultrasound parameters used to
enhance delivery with temperature-sensitive liposomes have also
varied widely with the center frequency typically ranging from 1
to 3 MHz and duty cycle ranging from∼10 to 100% (20, 31, 32).
MICROBUBBLES
Micron-scale gas bubbles with a stabilizing shell are used in ultra-
sound imaging to improve imaging of the blood pool and have
been widely applied in pre-clinical studies of enhanced drug deliv-
ery. The microbubble shell can be coupled to nanotherapeutics,
such as liposomes, or coated with a drug (33, 34). The gas core can
transport oxygen or other useful gas cargo, although for imaging
the gas core is selected to reduce diffusion through the shell mater-
ial (35). Alternative formulations in which liquid perfluorocarbon
particles are injected and change to a gaseous phase in vivo have
also been shown to have efficacy in the delivery of drugs to solid
tumors (36).
Reflections of ultrasound waves from tissue increase in propor-
tion to variations in density and compressibility of the medium
and therefore highly compressible gas bubbles produce strong
ultrasound echoes. These small bubbles expand and contract
in response to ultrasound waves. When driven at a frequency
near the resonance frequency that is determined by the size and
physical composition of the microbubble, a multi-fold expan-
sion can result. During the subsequent collapse, the velocity of
the microbubble wall can reach hundreds of meters per second
(37, 38), and the gas core can fragment into a set of small gas
particles (39). Also, during microbubble collapse, small jets can
impact nearby cell membranes and result in enhanced transport
of materials into the cell. In vitro studies in phantom materi-
als and ex vivo studies within tissues have confirmed that the
oscillating microbubble can travel through the vessel wall or can
affect the mechanical integrity of the vessel (40–42). Still, such jets
affect cells only within a distance on the order of tens of microns.
Therefore, the application of microbubbles to alter vascular, rather
than tumor cell, permeability is attractive since the vascular con-
centration is initially high and large numbers of microbubbles
are required to effectively change the membrane permeability of
a large fraction of cells within a tissue. Within the vasculature,
catheters have also been applied to direct streams of bubbles to a
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region of interest (43). Also, microbubble-enhanced gene delivery
has been widely studied since the biological amplification resulting
from transfection is expected to increase the impact of treatment
although the protocols have varied (44–48). Within such studies,
microbubbles and DNA have been co-injected or combined into
a single vehicle and the administration has been intratumoral or
intravascular. Typical ultrasound parameters for enhanced tumor
gene delivery have included a center frequency on the order of
1 MHz and a low pulse repetition frequency; however, the peak
negative ultrasound pressure has varied significantly and success-
ful transfection at higher ultrasound frequencies has also been
reported.
The ultrasound parameters used to increase vascular perme-
ability must be chosen carefully as insonation of microbubbles
with low ultrasound frequencies has been shown to reduce blood
flow (49). A parameter space for safe and effective use of microbub-
bles for enhancing vascular permeability has been established (41,
50–52). Many parameters, including microbubble dosage and size,
the ultrasound center frequency, pulse duration, pulse repetition
frequency, and the PNP determine the effect of the oscillating
microbubble on the surrounding tissue.
In addition to the formation of jets, physical mechanisms
exploited in microbubble-enhanced delivery include radiation
forces and microstreaming of fluid (53, 54). Radiation force refers
to a mechanism by which oscillating microbubbles or other parti-
cles are displaced, most typically in the direction of wave propaga-
tion (55–57). This displacement can be used to enhance vascular
targeting of a microbubble or microbubble-drug conjugate. Fur-
ther, local motion of fluid surrounding the oscillating bubble is
known as microstreaming and has been shown to increase cellular
uptake of therapeutics (53, 54).
One of the most important applications for the use of
microbubbles to enhance delivery has been the enhancement of
blood brain barrier (BBB) permeability (58–65). In general, the
technique consists of systemically injecting microbubbles and
insonifying the region of the brain where enhanced permeabil-
ity is desired. Here again, a parameter space has been established
within which enhanced BBB transport is achieved with minimal
hemorrhage and cell death. Still, the extension of these techniques
into the clinic is expected to require the use of real-time cavita-
tion detection, as individual variations in the skull penetration
of the ultrasound wave are significant and the therapeutic win-
dow for effective and safe therapy is relatively small (66). As noted
above, pre-clinical-application of microbubble-enhanced delivery
is widespread. In addition, the authors are aware of yet unreported
small clinical studies of microbubble-enhanced delivery to solid
tumors.
APPLICATION OF IMAGING TECHNOLOGY
A major reason for the expansion of the application of thera-
peutic ultrasound is the development of methods to monitor the
treated location and the temperature using MRI (67) or ultrasound
(68). While mild hyperthermia (CEM 43< 0.5) is associated with
increased metabolism, blood flow, and tissue repair, higher ther-
mal doses are associated with enhanced cell death and therefore the
methods to carefully control and monitor the delivered tempera-
ture are critically important (69). Image guidance using nuclear
medicine techniques is also attractive due to their high sensitivity
and the opportunity for quantitation of delivery (70, 71). By radi-
olabeling nanoparticles, the rate and magnitude of extravasation
can be directly estimated from PET data (71). Even with the rela-
tively low spatial resolution of PET (∼1 mm), the penetration of
nanoparticle-based therapeutics has been assessed and shown to
differ from small molecular weight agents (72).
In order to fully evaluate the enhanced penetration of a drug
resulting from ultrasound, multiple imaging labels can be incor-
porated with drug accumulation and penetration assessed at the
whole body, organ, and cellular scales (8, 9, 70, 73, 74). Multiple
MRI protocols can be proposed for the guidance of ultrasound
therapies including diffusion-weighted (75, 76), T2-weighted (77,
78), and contrast enhanced T1-weighted imaging (79–81), fluid
attenuated inversion recovery (FLAIR) (82), heteronuclear (23Na)
(83), spectroscopy (84), and displacement sensitive sequences via
MR elastography (85). Following HIFU ablation of the prostate,
gadolinium enhanced MRI is often used to evaluate the extent of
tissue damage. Although contrast enhanced T1-weighted MRI can
detect tissue damage following HIFU ablation (86, 87), it does not
correlate to histological results (intensity of necrosis, presence of
foci of viable cancer) immediately following HIFU (87). However,
for follow-up examinations, DCE MRI has demonstrated good
sensitivity and diffusion MRI has shown specificity in identifying
tumor progression after HIFU ablation (75, 88).
In addition to endogenous contrast mechanisms that can be
used to guide and assess ultrasound therapies, exogenous agents
can be used to report on specific changes. For example, co-
administration of two paramagnetic contrast agents (gadolinium
and thulium) within liposomal drug carriers has been previously
utilized to follow internalization and cellular trafficking of the
vehicle (89). Similarly, multi modal liposomal agents spanning
CT and MRI have been used to assess the penetration of lipo-
somes within tumors and have been proposed for cross modality
registration and as a means to guide imaging-based interventions
(73, 74). Many physiological parameters can also be assessed by
MRI and coupled with the soft tissue anatomical information
motivate MRI as an excellent tool for guiding thermal therapies
(90, 91).
In addition to the role of MRI in the assessment of drug
penetration and distribution, MR thermometry can be applied
to monitor the temperature of a region during an interven-
tion (92–100). The proton resonance frequency (PRF) of water
is frequently used to detect changes in temperature (101) both
because it has a thermal coefficient that is linear over a wide
temperature range and, excepting adipose tissue, the PRF shift
has little dependence on tissue type even following coagulation
(99, 102). The PRF shift can be measured rapidly with gradient
echo sequences, which is advantageous during thermal therapies
where high temporal resolution is desirable, especially during abla-
tive processes, to avoid damage to surrounding tissue. Further
increases in temporal resolution can be gained via partial par-
allel imaging techniques using phased arrays (103–105) utilizing
various algorithms (105).
Neither clinical focused ultrasound (FUS) systems, which typ-
ically operate around 1 MHz (106, 107), nor clinical MR scanners
(e.g., 1.5, or 3 T) are ideal for small animal imaging. In the former,
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the focal spot depth may encompass an appreciable portion of
the animal, while the latter may have insufficient signal-to-noise
ratio (SNR) to easily obtain detailed images of murine tumors.
The smaller focal depth at higher FUS frequencies makes them
more suitable for pre-clinical imaging of small animals (108).
High field scanners are especially useful for small animal ther-
mal imaging because in addition to providing higher SNR, which
can be used for higher spatial resolutions, they also improve the
sensitivity of thermal measurements made with the PRF shift
method, which itself has a first order dependence on magnetic
field strength.
FUTURE APPLICATIONS
The use of the thermal and mechanical effects of ultrasound to
enhance delivery to solid tumors is expanding. With the increas-
ing availability of MRI-guided high intensity focused ultrasound,
well-controlled and calibrated clinical studies are feasible. Both the
use of ultrasound to alter tissue properties and to release a drug
from a carrier are in widespread pre-clinical evaluation. With the
addition of microbubbles, drug penetration through the endothe-
lium can also be increased, although the protocols are currently
more complex due to the need to co-inject the therapeutic and
microbubbles.
In the future, the effects of ultrasound may transcend the
local effect through enhanced immune response. The addition of
immunotherapy to standard-of-care cancer therapies has shown
evidence of efficacy in the pre-clinical and clinical settings (109–
115). The immune system is often tolerant to antigens presented by
the tumor and therefore strategies to induce tumor-specific immu-
nity must overcome obstacles including: insufficient and dysfunc-
tional populations of antigen-presenting cells and lymphocytes,
the difficulty of inducing potent immunity without inducing
unacceptable autoimmune toxicities, the low immunogenicity of
antigens expressed by tumor cells, and immunoregulatory path-
ways that dampen the tumor-specific immune response (116). The
use of ultrasound ablation to generate an immune response has
been shown to be a promising technique for immune activation
(110–112, 114, 115, 117–121). Ultrasound ablation is thought to
act through dendritic cell maturation and T-cell immunity (122),
and is particularly advantageous because it is completely non-
invasive, can be controlled with high spatial precision and uses no
harmful ionizing radiation (123, 124).
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